Literature DB >> 31784925

The linguistic validation process of the Vanderbilt Head and Neck Symptom Survey - Italian Version (VHNSS-IT).

Marta Maddalo1, Michela Buglione2, Nadia Pasinetti3, Luca Triggiani2, Loredana Costa2, Stefano M Magrini2, Barbara A Murphy4.   

Abstract

PURPOSE: To linguistically validate the Italian translation of the Vanderbilt Head and Neck Symptom Survey (VHNSS), there is a patient-reported outcome measure to screen for symptoms in the head and neck cancer (HNC) patients population. The goal was to ensure conceptually equivalence with the original version and maintain clarity, ease of use and understanding.
METHODS: We conducted a multi-step linguistic process (forward translation, backward translation and patient testing) to generate and validate an Italian translation of the VHNSS.
RESULTS: Two intermediate Italian versions were created: The first Italian version was derived from a reconciliation of the three forward translations, and the second Italian version was derived from changes in the first version after the backward translation step. All investigators involved actively discussed possible solutions to produce a translated instrument that maintained a reading and comprehension level accessible by most respondents, without altering the meaning and content of the original source. During the patient testing step, only two patients reported problems with items comprehension and the rate of comprehension problems per single item was lower than expected. This phase allowed patients to give suggestion in order to make items clearer and easier to understand: 43% of patients proposed a revision of the survey during the face-to-face interview, and most of these suggestions were retained.
CONCLUSIONS: A valid multi-step process leads to the creation of the final version of the VHNSS-IT, a suitable instrument to screen for symptoms in the Italian HNC patients population and an official measurement tool that can be used in cooperative research group.

Entities:  

Keywords:  Head and neck cancer; Patient reported outcomes (PRO); Radiotherapy; Symptoms screening

Mesh:

Year:  2019        PMID: 31784925     DOI: 10.1007/s11547-019-01105-w

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  21 in total

Review 1.  Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.

Authors:  Charles S Cleeland; Jeff A Sloan
Journal:  J Pain Symptom Manage       Date:  2010-06       Impact factor: 3.612

2.  The content validity index: are you sure you know what's being reported? Critique and recommendations.

Authors:  Denise F Polit; Cheryl Tatano Beck
Journal:  Res Nurs Health       Date:  2006-10       Impact factor: 2.228

3.  Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation.

Authors:  A Greco; E Orlandi; A Mirabile; S Takanen; C Fallai; N A Iacovelli; A Rimedio; E Russi; M Sala; D Monzani; D I Rosenthal; G B Gunn; P Steca; L Licitra; P Bossi
Journal:  Support Care Cancer       Date:  2015-03-21       Impact factor: 3.603

Review 4.  Toxicity in head and neck cancer: a review of trends and issues.

Authors:  A Trotti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

5.  Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation.

Authors:  Barbara A Murphy; Mary S Dietrich; Nancy Wells; Kathleen Dwyer; Sheila H Ridner; Heidi J Silver; Jill Gilbert; Christine H Chung; Anthony Cmelak; Brian Burkey; Wendell G Yarbrough; Robert Sinard; James Netterville
Journal:  Head Neck       Date:  2010-01       Impact factor: 3.147

6.  Rehabilitation outcomes of long-term survivors treated for head and neck cancer.

Authors:  M F de Boer; J F Pruyn; B van den Borne; P P Knegt; R M Ryckman; C D Verwoerd
Journal:  Head Neck       Date:  1995 Nov-Dec       Impact factor: 3.147

7.  Psychosocial problems in head-and-neck cancer patients and their change with time since diagnosis.

Authors:  Y Rapoport; S Kreitler; S Chaitchik; R Algor; K Weissler
Journal:  Ann Oncol       Date:  1993-01       Impact factor: 32.976

Review 8.  The prognostic significance of patient-reported outcomes in cancer clinical trials.

Authors:  Carolyn C Gotay; Crissy T Kawamoto; Andrew Bottomley; Fabio Efficace
Journal:  J Clin Oncol       Date:  2008-01-28       Impact factor: 44.544

Review 9.  Systemic and global toxicities of head and neck treatment.

Authors:  Barbara A Murphy; Jill Gilbert; Sheila H Ridner
Journal:  Expert Rev Anticancer Ther       Date:  2007-07       Impact factor: 4.512

Review 10.  A structured review and theme analysis of papers published on 'quality of life' in head and neck cancer: 2000-2005.

Authors:  S N Rogers; S A Ahad; A P Murphy
Journal:  Oral Oncol       Date:  2007-06-27       Impact factor: 5.337

View more
  3 in total

1.  Intrahepatic cholangiocarcinoma and its differential diagnosis at MRI: how radiologist should assess MR features.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Alessandro Ottaiano; Guglielmo Nasti; Michelearcangelo La Porta; Ginevra Danti; Salvatore Cappabianca; Carmen Cutolo; Antonella Petrillo; Francesco Izzo
Journal:  Radiol Med       Date:  2021-11-29       Impact factor: 3.469

Review 2.  Role of Texture Analysis in Oropharyngeal Carcinoma: A Systematic Review of the Literature.

Authors:  Eleonora Bicci; Cosimo Nardi; Leonardo Calamandrei; Michele Pietragalla; Edoardo Cavigli; Francesco Mungai; Luigi Bonasera; Vittorio Miele
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

3.  Translation and cross-cultural adaption of the Chinese version of the Vanderbilt Head and Neck Symptom Survey version 2.0: a tool for oral symptom assessment in head and neck cancer patients.

Authors:  Min Jin; Li Sun; Rui Meng; Wenjing Wang; Rui Sun; Jing Huang; You Qin; Bian Wu; Qian Ding; Gang Peng; Tao Zhang; Kunyu Yang
Journal:  Health Qual Life Outcomes       Date:  2021-01-21       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.